Therapy for clearing heat and resolving phlegm in treatment of systemic inflammatory response syndrome in acute deterioration stage of chronic obstructive pulmonary disease: A randomized controlled trial

Journal of Chinese Integrative Medicine

Volumn 7, Issue 2, 2009, Pages 105-109

  Chen, Ning ^a   Li, Hui ^a   Zhao, Li Yun ^a   Liu, Jian Bo ^b   Huang, Qin ^a   Wang, Tong Han ^a   Hao, Xiao Mei ^a  

^a GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chronic obstructive pulmonary disease; Clearing heat and resolving phlegm; Procalcitonin; Randomized controlled trial; Systemic inflammatory response syndrome

Indexed keywords

PROCALCITONIN;

AGED; ALTERNATIVE MEDICINE; ARTICLE; CHINESE MEDICINE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC PREDISPOSITION; HORMONE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; LUNG CLEARANCE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; SCORING SYSTEM; SPUTUM; SYMPTOMATOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERAPY EFFECT;

AGED; AGED, 80 AND OVER; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; INTEGRATIVE MEDICINE; MALE; MEDICINE, CHINESE TRADITIONAL; PHYTOTHERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 68949088689     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20090202     Document Type: Article

References (10)

1. Kuang TG, Xu ZY, He YF, Zhang HY, Zhou JQ, Li XH, Zhang SM, Wang Y. Influence of systemic inflammatory response syndrome on severity and fatality rate in acute deterioration stage of chronic obstructive pulmonary disease. Zhongguo Yi Kan. 2003; 38 (1): 29-31.
2. Lai SL. Clinical research methodology in integrated traditional Chinese and Western medicine. Beijing: Science Press. 2003: 54-56.
3. Fabbri LM, Hurd SS; GOLD scientific Committee. Global strategy for the diagnosis, management and prevention of COPD, 2003 update. Eur Respir J. 2003; 22(1): 1-2.
4. Wang YY, Lu ZL. Internal medicine of traditional Chinese medicine. 6th ed. Shanghai: Shanghai Scientific and Technical Publishers. 2002.
5. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101(8): 1644-1655.
6. Zheng XY. Guidelines of clinical research on Chinese new herbal medicines. Beijing: China Medical Pharmaceutical Science & Technology Publishing House. 2002.
7. Wang J, Gao Z, Liu L, Wang XQ. Investigation of the relationships among CRP, SF, BS and SIRS in COPD patients in acute stage and its clinical significance. Lin Chuang Fei Ke Za Zhi. 2006; 11(3): 327-328.
8. Chang C, Yao WZ, Chen YH, Liu ZY, Zhang XW. The changes and clinical implications of serum procalcitonin in acute exacerbations of chronic obstructive pulmonary disease. Zhonghua Jie He He Hu Xi Za Zhi. 2006; 29 (7), 444-447.
9. Zheng ZS, Li QY, Chen CQ. The detection and application of serum procalcitonin in serious pneumonia. Hebei Yi Xue. 2004; 10(6): 529-531.
10. Sun YY, Li ZJ, Ren XS, Wang JD. Syndrome differentiation treatment of systemic inflammatory response syndrome in traditional Chinese medicine. Zhongguo Zhong Yi Ji Zheng. 2005; 14(4): 340-341.